Athanasios G Tzioufas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11876064/publications.pdf

Version: 2024-02-01

202 papers

9,592 citations

28190 55 h-index ⁴²²⁹¹ **92**

g-index

206 all docs 206 docs citations

206 times ranked 10159 citing authors

#	Article	IF	Citations
1	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.5	1,114
2	Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells. Immunity, 2019, 51, 573-589.e8.	6.6	336
3	Treatment of Primary Sjögren Syndrome. JAMA - Journal of the American Medical Association, 2010, 304, 452.	3.8	309
4	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.5	307
5	Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis and Rheumatism, 1996, 39, 767-772.	6.7	230
6	Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nature Reviews Rheumatology, 2010, 6, 529-537.	3.5	206
7	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 1161-1168.	0.5	200
8	Pathogenesis of Sjögren's syndrome: What we know and what we should learn. Journal of Autoimmunity, 2012, 39, 4-8.	3.0	191
9	Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. Journal of Autoimmunity, 2007, 29, 219-228.	3.0	177
10	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the Rheumatic Diseases, 2007, 66, 732-739.	0.5	175
11	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. Medicine (United) Tj ETQq1	1 0.78431 0.4	.4 <u>rg</u> BT /Overl
12	Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjogren Syndrome. Medicine (United States), 2000, 79, 241-249.	0.4	170
13	?Lymphoid? chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sj�gren's syndrome patients: Possible participation in lymphoid structure formation. Arthritis and Rheumatism, 2001, 44, 408-418.	6.7	165
14	Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nature Reviews Rheumatology, 2012, 8, 399-411.	3.5	152
15	Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Annals of the Rheumatic Diseases, 2020, 79, 1661-1663.	0.5	146
16	Cryoglobulinaemia. Nature Reviews Disease Primers, 2018, 4, 11.	18.1	143
17	Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17609-17614.	3.3	140
18	Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. American Journal of Medicine, 2000, 108, 198-204.	0.6	133

#	Article	IF	CITATIONS
19	Clinically Significant Renal Involvement in Primary SjĶgren's Syndrome: Clinical Presentation and Outcome. Arthritis and Rheumatism, 2013, 65, 2945-2953.	6.7	129
20	Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. Journal of Autoimmunity, 2006, 26, 165-171.	3.0	122
21	Classification criteria for Sjogren's syndrome: A critical review. Journal of Autoimmunity, 2012, 39, 9-14.	3.0	122
22	Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. Rheumatology, 2016, 55, 789-800.	0.9	120
23	A comprehensive review of autoantibodies in primary Sj \tilde{A} ¶gren's syndrome: Clinical phenotypes and regulatory mechanisms. Journal of Autoimmunity, 2014, 51, 67-74.	3.0	114
24	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq0 0 0 rg	BT/Qverlo	ck 10 Tf 50 5
25	Sjögren's Syndrome—Study of Autoantigens and Autoantibodies. Clinical Reviews in Allergy and Immunology, 2007, 32, 238-251.	2.9	102
26	Update on Sj \tilde{A} ¶gren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Practice and Research in Clinical Rheumatology, 2007, 21, 989-1010.	1.4	101
27	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
28	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. Journal of Autoimmunity, 2014, 51, 89-98.	3.0	99
29	Treatment of rheumatoid arthritis: Unraveling the conundrum. Journal of Autoimmunity, 2015, 65, 1-18.	3.0	99
30	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmunity Reviews, 2016, 15, 1145-1160.	2.5	87
31	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmunity Reviews, 2017, 16, 523-541.	2.5	87
32	Cellular microRNAs (miRNAs) and Sjögren's syndrome: Candidate regulators of autoimmune response and autoantigen expression. Journal of Autoimmunity, 2011, 37, 129-135.	3.0	86
33	Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmunity Reviews, 2005, 4, 8-15.	2.5	85
34	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. PLoS ONE, 2013, 8, e55843.	1.1	83
35	Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. Journal of Rheumatology, 2002, 29, 2129-35.	1.0	80
36	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	2.5	79

#	Article	IF	Citations
37	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. PLoS ONE, 2015, 10, e0116189.	1.1	77
38	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. Journal of the Neurological Sciences, 2014, 347, 143-147.	0.3	76
39	Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus. Correlation with anemia. Arthritis and Rheumatism, 1997, 40, 2212-2216.	6.7	74
40	Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. Journal of Autoimmunity, 2012, 39, 234-239.	3.0	74
41	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 798-802.	0.9	73
42	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of Hepatology, 2017, 66, 1282-1299.	1.8	73
43	Clinical picture, outcome and predictive factors of lymphoma in SjÓ§gren syndrome. Autoimmunity Reviews, 2015, 14, 641-649.	2.5	68
44	Insight into pathogenesis of Sj \tilde{A} q gren's syndrome: Dissection on autoimmune infiltrates and epithelial cells. Clinical Immunology, 2017, 182, 30-40.	1.4	67
45	Medical data quality assessment: On the development of an automated framework for medical data curation. Computers in Biology and Medicine, 2019, 107, 270-283.	3.9	67
46	Prevalence of hepatitis C serum antibody in autoimmune diseases. Journal of Autoimmunity, 2009, 32, 261-266.	3.0	65
47	Sjögren's Syndrome: Autoantibodies to Cellular Antigens. International Archives of Allergy and Immunology, 2000, 123, 46-57.	0.9	63
48	Autoimmune response and target autoantigens in Sjogren's syndrome. European Journal of Clinical Investigation, 2010, 40, 1026-1036.	1.7	63
49	Minor Salivary Gland Inflammatory Lesions in SjĶgren Syndrome: Do They Evolve?. Journal of Rheumatology, 2013, 40, 1566-1571.	1.0	62
50	The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clinica Chimica Acta, 2004, 340, 1-25.	0.5	61
51	Neuroendocrine Dysfunction in Sjögren's Syndrome. NeuroImmunoModulation, 2008, 15, 37-45.	0.9	61
52	The contribution of epigenetics in SjÃf¶grenââ,¬â,,¢s Syndrome. Frontiers in Genetics, 2014, 5, 71.	1.1	60
53	A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome–Related Lymphoproliferation. Arthritis and Rheumatology, 2015, 67, 2732-2741.	2.9	60
54	B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: Tools to study the regulation of the autoimmune response. Journal of Autoimmunity, 2010, 35, 256-264.	3.0	59

#	Article	IF	Citations
55	Classification criteria of Sjögren's syndrome. Journal of Autoimmunity, 2014, 48-49, 42-45.	3.0	58
56	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. European Respiratory Journal, 2022, 60, 2102951.	3.1	56
57	Lymphomagenesis in Sj \tilde{A} ¶gren's syndrome: Predictive biomarkers towards precision medicine. Autoimmunity Reviews, 2019, 18, 137-143.	2.5	54
58	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5, e001064.	1.8	53
59	Primary SjÓ§gren's syndrome: Clinical phenotypes, outcome and the development of biomarkers. Autoimmunity Reviews, 2016, 15, 695-703.	2.5	52
60	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. Journal of the Neurological Sciences, 2013, 334, 123-125.	0.3	51
61	Epigenetic perspectives on systemic autoimmune disease. Journal of Autoimmunity, 2019, 104, 102315.	3.0	50
62	Sjögren's Syndrome. Advances in Experimental Medicine and Biology, 1999, , 127-134.	0.8	50
63	Unmasking the Anti-La/SSB Response in Sera From Patients With Sjogren's Syndrome by Specific Blocking of Anti-idiotypic Antibodies to La/SSB Antigenic Determinants. Molecular Medicine, 2002, 8, 293-305.	1.9	48
64	Autoantibodies in Sj \tilde{A} gren's syndrome: Clinical presentation and regulatory mechanisms. Presse Medicale, 2012, 41, e451-e460.	0.8	48
65	Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with SjĶgren's syndrome. Annals of the Rheumatic Diseases, 2017, 76, 625-628.	0.5	45
66	Primary Sjögren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096.	2.2	45
67	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	3.0	45
68	Idiotype, anti-idiotype network of autoantibodies. Autoimmunity Reviews, 2010, 9, 631-633.	2.5	44
69	Anti-LA/SSB antiidiotypic antibodies in maternal serum: A marker of low risk for neonatal lupus in an offspring. Arthritis and Rheumatism, 2006, 54, 2228-2234.	6.7	40
70	Autoantibodies to intracellular autoantigens and their B-cell epitopes: Molecular Probes to Study the Autoimmune Response. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 203-248.	2.7	40
71	Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome. Journal of Autoimmunity, 2015, 65, 30-37.	3.0	39
72	Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers. Immunologic Research, 2017, 65, 331-344.	1.3	37

#	Article	IF	CITATIONS
73	Fine Epitope Specificity of Anti-erythropoietin Antibodies Reveals Molecular Mimicry With HIV-1 p17 Protein: A Pathogenetic Mechanism for HIV-1–Related Anemia. Journal of Infectious Diseases, 2011, 204, 902-911.	1.9	36
74	Predictive markers of lymphomagenesis in Sjögren's syndrome: From clinical data to molecular stratification. Journal of Autoimmunity, 2019, 104, 102316.	3.0	36
7 5	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	2.5	36
76	Idiotype–anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289–308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. Journal of Autoimmunity, 2003, 21, 17-26.	3.0	35
77	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clinical Rheumatology, 2019, 38, 125-132.	1.0	35
78	The Role of Chaperone Proteins in Autoimmunity. Annals of the New York Academy of Sciences, 2006, 1088, 52-64.	1.8	32
79	Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212639.	0.5	32
80	Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. Clinical and Experimental Rheumatology, 2015, 33, 216-24.	0.4	32
81	Current aspects of pathogenesis in Sjögren's syndrome. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 325-334.	1.2	31
82	Ultrasonography of salivary glands: an evolving approach for the diagnosis of Sjögren's syndrome. Nature Clinical Practice Rheumatology, 2008, 4, 454-455.	3.2	30
83	Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmuneâ€associated congenital heart block. Arthritis and Rheumatism, 2011, 63, 2783-2789.	6.7	30
84	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Journal of Neuroimmunology, 2015, 289, 8-11.	1.1	30
85	Autoantibodies to La/SSB in Patients with Primary Sjögren's Syndrome (pSS) are Associated with Upregulation of La/SSB mRNA in Minor Salivary Gland Biopsies (MSGs). Journal of Autoimmunity, 1999, 13, 429-434.	3.0	29
86	Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. Clinical Rheumatology, 2018, 37, 737-747.	1.0	29
87	Autoantibodies to hmg-17 nucleosomal protein in autoimmune rheumatic diseases. Arthritis and Rheumatism, 1993, 36, 955-961.	6.7	28
88	A major Sm epitope anchored to sequential oligopeptide carriers is a suitable antigenic substrate to detect anti-Sm antibodies. Journal of Immunological Methods, 1998, 220, 59-68.	0.6	28
89	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Scientific Reports, 2017, 7, 7354.	1.6	28
90	COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Frontiers in Immunology, 2021, 12, 719023.	2.2	28

#	Article	IF	CITATIONS
91	Sjögren's Syndrome: The Clinical Spectrum of Male Patients. Journal of Clinical Medicine, 2020, 9, 2620.	1.0	26
92	Salivary Gland Ultrasonography in Sjögren's Syndrome: A European Multicenter Reliability Exercise for the HarmonicSS Project. Frontiers in Medicine, 2020, 7, 581248.	1.2	26
93	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. Clinical Immunology, 2016, 173, 157-160.	1.4	24
94	TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients. Journal of Immunology Research, 2018, 2018, 1-8.	0.9	24
95	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648.	3.0	24
96	Saliva proteomics is a promising tool to study Sjögren syndrome. Nature Reviews Rheumatology, 2015, 11, 202-203.	3.5	23
97	Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Research and Therapy, 2010, 12, R208.	1.6	21
98	Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis. Journal of Rheumatology, 2011, 38, 1304-1308.	1.0	20
99	RNA Recognition Motif (RRM) of La/SSB: The Bridge for Interparticle Spreading of Autoimmune Response to U1-RNP. Molecular Medicine, 2010, 16, 19-26.	1.9	19
100	COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. Journal of Autoimmunity, 2021, 123, 102687.	3.0	19
101	Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981–2021). Rheumatology, 2022, 61, 3576-3585.	0.9	19
102	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics, 2016, 13, 163-178.	2.1	17
103	Trial of canakinumab, an IL- $1\hat{l}^2$ receptor antagonist, in patients with inclusion body myositis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e581.	3.1	17
104	Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. Rheumatology, 2022, 61, 1639-1644.	0.9	17
105	Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Molecular Medicine, 2002, 8, 293-305.	1.9	16
106	Functional expression of the alpha 2-macroglobulin receptor CD91 in salivary gland epithelial cells. Journal of Autoimmunity, 2009, 33, 141-146.	3.0	15
107	Zinc Ion Dependent B-Cell Epitope, Associated with Primary Sjogren's Syndrome, Resides within the Putative Zinc Finger Domain of Ro60kD Autoantigen:Â Physical and Immunologic Properties. Journal of Medicinal Chemistry, 2004, 47, 4327-4334.	2.9	13
108	Ablation of the Chaperone Protein ERdj5 Results in a Sjögren's Syndrome-Like Phenotype in Mice, Consistent With an Upregulated Unfolded Protein Response in Human Patients. Frontiers in Immunology, 2019, 10, 506.	2.2	13

#	Article	IF	CITATIONS
109	SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study. Viruses, 2021, 13, 1143.	1.5	13
110	Hypocomplementemia at Diagnosis of Pauci-immune Glomerulonephritis Is Associated With Advanced Histopathological Activity Index and High Probability of Treatment Resistance. Kidney International Reports, 2021, 6, 2425-2435.	0.4	13
111	Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract. Frontiers in Genetics, 2017, 8, 65.	1.1	11
112	Machine Learning Approaches on High Throughput NGS Data to Unveil Mechanisms of Function in Biology and Disease. Cancer Genomics and Proteomics, 2021, 18, 605-626.	1.0	11
113	Common and rare forms of vasculitis associated with SjÃ \P gren's syndrome. Current Opinion in Rheumatology, 2020, 32, 21-28.	2.0	10
114	New frontiers in precision medicine for Sjogren's syndrome. Expert Review of Clinical Immunology, 2021, 17, 127-141.	1.3	10
115	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. Computers in Biology and Medicine, 2021, 134, 104520.	3.9	10
116	Diagnostic value of ultrasonography in Sjögren's syndrome. Nature Reviews Rheumatology, 2014, 10, 450-452.	3.5	9
117	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers, 2020, 12, 3520.	1.7	9
118	Overcoming the Barriers That Obscure the Interlinking and Analysis of Clinical Data Through Harmonization and Incremental Learning. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 83-90.	1.7	9
119	Autoantibodies in Autoimmune Diseases: Clinical and Critical Evaluation. Israel Medical Association Journal, 2016, 18, 519-524.	0.1	9
120	Analysis of NLRP3, MVK and TNFRSF1A variants in adult Greek patients with autoinflammatory symptoms. Clinical and Experimental Rheumatology, 2018, 36, 86-89.	0.4	9
121	Linear epitopes of two different autoantigens-La/SSB and myelin basic proteinâ€"with a high degree of molecular similarity, cause different humoral immune responses. Journal of Autoimmunity, 2003, 21, 47-57.	3.0	8
122	Predicting lymphoma outcomes and risk factors in patients with primary Sjögren's Syndrome using gradient boosting tree ensembles. , 2019, 2019, 2165-2168.		8
123	Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. Autoimmunity Reviews, 2021, 20, 102742.	2.5	8
124	A computational workflow for the detection of candidate diagnostic biomarkers of Kawasaki disease using time-series gene expression data. Computational and Structural Biotechnology Journal, 2021, 19, 3058-3068.	1.9	8
125	Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 705079.	2.2	8
126	One year in review 2020: pathogenesis of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 3-9.	0.4	8

#	Article	IF	CITATIONS
127	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 80-84.	0.4	8
128	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome. Journal of Clinical Medicine, 2021, 10, 644.	1.0	7
129	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484.	1.9	7
130	Searching for the "X factor" in Sj \tilde{A} ¶gren's syndrome female predilection. Clinical and Experimental Rheumatology, 2021, 39, 206-214.	0.4	7
131	Salivary gland imaging techniques for the diagnosis of Sjögren's syndrome. International Journal of Clinical Rheumatology, 2009, 4, 321-327.	0.3	6
132	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. Journal of Autoimmunity, 2016, 72, 57-64.	3.0	6
133	Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center. Rheumatology, 2020, 59, 1241-1246.	0.9	6
134	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. Frontiers in Immunology, 2021, 12, 683623.	2.2	6
135	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity, 2015, 48, 453-9.	1.2	6
136	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2022, 131, 102846.	3.0	6
137	How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study. Autoimmunity Reviews, 2018, 17, 1124-1133.	2.5	5
138	A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness. Vaccine, 2021, 39, 1593-1597.	1.7	5
139	Deregulation of the Kallikrein Protease Family in the Salivary Glands of the Sjögren's Syndrome ERdj5 Knockout Mouse Model. Frontiers in Immunology, 2021, 12, 693911.	2.2	5
140	Update on Sjögren's Syndrome 2018. Mediterranean Journal of Rheumatology, 2018, 29, 193-198.	0.3	5
141	Hashimoto Thyroiditis, Anti-Parietal Cell Antibodies: Associations With Autoimmune Diseases and Malignancies. Frontiers in Endocrinology, 2022, 13, 860880.	1.5	5
142	Towards the Establishment of a Biomedical Ontology for the Primary Sjögren's Syndrome. , 2018, 2018, 4089-4092.		4
143	Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of SjA¶gren's Syndrome Patients. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 49-56.	1.7	4
144	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	1.3	4

#	Article	IF	CITATIONS
145	Interaction of Human Salivary Gland Epithelial Cells with B Lymphocytes: Implications in the Pathogenesis of Sjögren's Syndrome. Mediterranean Journal of Rheumatology, 2020, 31, 424.	0.3	4
146	Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study. Clinical and Experimental Rheumatology, 2017, 35, 192-200.	0.4	4
147	Sjögren's syndrome towards precision medicine: the challenge of harmonisation and integration of cohorts. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 175-184.	0.4	4
148	Multiple additive regression trees with hybrid loss for classification tasks across heterogeneous clinical data in distributed environments: a case study., 2021, 2021, 1670-1673.		4
149	SP0190â€2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJöGRENâ€ S SYNDROME WITH TOP AND SYSTEMIC THERAPIES. , 2019, , .	ICAL	3
150	Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?. Current Vascular Pharmacology, 2020, 18, 425-430.	0.8	3
151	Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. International Journal of Molecular Sciences, 2021, 22, 4099.	1.8	3
152	Occurrence and Antigenic Specificity of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) in Systemic Autoimmune Diseases. Cells, 2021, 10, 2128.	1.8	3
153	Patient with ankylosing spondylitis and scleroderma renal crisis. Mediterranean Journal of Rheumatology, 2018, 29, 86-88.	0.3	3
154	Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases. Current Vascular Pharmacology, 2020, 18, 533-537.	0.8	3
155	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in SjA¶gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 719-720.	0.4	3
156	Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia. Lancet, The, 2020, 396, 853.	6.3	2
157	Role of miR200b-5p miRNA in lymphomagenesis associated with Sjögren's syndrome (SS). Mediterranean Journal of Rheumatology, 2018, 29, 56-58.	0.3	2
158	Panniculitis: an unusual presenting manifestation of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 126-8.	0.4	2
159	Limited efficacy of targeted treatments in Sjögren's syndrome: why?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 27-28.	0.4	2
160	Severe cutaneous hand infection: Mycobacterium marinum in an immunosuppressed patient. Clinical and Experimental Rheumatology, 2018, 36, 1117.	0.4	2
161	Enhancing medical data quality through data curation: a case study in primary Sj $ ilde{A}$ gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 90-96.	0.4	2
162	Type-III interferons in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 245-252.	0.4	2

#	Article	IF	Citations
163	EULAR Sjögren's syndrome study group: an eSSential way to address the unmet needs of the disease. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 23-24.	0.4	2
164	Sjögren's syndrome. International Journal of Clinical Rheumatology, 2013, 8, 517-520.	0.3	1
165	DNA Methylation Studies in Saliva of Patients with Sjögren's Syndrome. Mediterranean Journal of Rheumatology, 2021, 32, 176.	0.3	1
166	Pathogenetic Aspects of Primary Sjögren's Syndrome. , 2011, , 33-53.		1
167	B-cell Epitopes of Sjögren's Syndrome-Related Autoantigens Ro/SSA and La/SSB. , 2011, , 133-149.		1
168	Sjögren syndrome. , 2011, , 1339-1350.e1.		1
169	Autoantibodies in Sjögren's Syndrome and Laboratory Markers. Rare Diseases of the Immune System, 2016, , 293-308.	0.1	1
170	Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 155-164.	0.4	1
171	Autoimmune or infectious disease? That is the question. Clinical and Experimental Rheumatology, 2018, 36, 517-518.	0.4	1
172	Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 239-240.	0.4	1
173	Autoimmune epithelitis beyond the exocrine glands: an unusual case of anti-Ro/La and Scl-70 lymphocytic interstitial pneumonia. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 249-251.	0.4	1
174	The necessity of novel biomarkers in primary SjÃ \P gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 16-18.	0.4	1
175	Variation in primary Sjögren's syndrome care among European countries. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 27-28.	0.4	1
176	Idiopathic retroperitoneal fibrosis: clinical features, treatment modalities, relapse rate in Greek patients and a review of the literature. Clinical and Experimental Rheumatology, 2021, , .	0.4	1
177	Idiopathic retroperitoneal fibrosis: clinical features, treatment modalities, relapse rate in Greek patients and a review of the literature. Clinical and Experimental Rheumatology, 0, , .	0.4	1
178	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sjögren's Syndrome. International Journal of Molecular Sciences, 2021, 22, 13441.	1.8	1
179	Patient-reported experience and health-related quality of life in patients with primary Sjögren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, 39, 123-130.	0.4	1
180	Late and booster <scp>antiâ€SARSâ€CoV</scp> â€2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by <scp>XXXX</scp> et al. ACR Open Rheumatology, 2022, 4, 645-646.	0.9	1

#	Article	IF	CITATIONS
181	Risk factors for lymphoproliferation and mortality in Sjögren's syndrome. Future Rheumatology, 2006, 1, 607-616.	0.2	O
182	SS-B (La) AUTOANTIBODIES. , 2007, , 239-246.		0
183	Punctal occlusion in Sjögren's syndrome needs clarification. Nature Reviews Rheumatology, 2012, 8, 752-752.	3.5	0
184	SS-B (La) Autoantibodies. , 2014, , 247-253.		0
185	Sjögren's Syndrome. , 2015, , 883-889.		0
186	07.08â€Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
187	08.37â€Thrombospondin-1 is highly expressed by salivary gland epithelial cells of sjögren's syndrome patients, both constitutively and upon exposure to necrotic cells debris. , 2017, , .		0
188	Response to: â€~Is miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands?' by Nocturne et al. Annals of the Rheumatic Diseases, 2019, 78, e96-e96.	0.5	0
189	Gynecological and Reproductive Complications in Primary Sjögren's Syndrome. , 2011, , 333-346.		0
190	Current Treatment of Extraglandular Manifestations with Disease-Modifying and Immunosuppressive Agents. , 2011 , , $337-344$.		0
191	Sjögren's Syndrome. , 2014, , 1069-1075.		0
192	Sjogren's Syndrome (Ss) in Progressive Systemic Sclerosis (SSc). In Clinical Practice, 2021, , 281-297.	0.1	0
193	Diagnosis and Management of a Young Girl With Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) Linked to a Novel Mutation. Cureus, 2020, 12, e10766.	0.2	0
194	Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 29-39.	0.4	0
195	A Training Tool to support the management and diagnosis of Sjögren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 174-179.	0.4	0
196	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 189-194.	0.4	0
197	Combined seronegativity in Sjögren's syndrome. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
198	Searching for the "X factor" in SjÃ \P gren's syndrome female predilection. Clinical and Experimental Rheumatology, 2021, , .	0.4	0

#	Article	IF	CITATIONS
199	Patient-reported experience and health-related quality of life in patients with primary Sj $ ilde{A}$ gren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, , .	0.4	O
200	A federated AI strategy for the classification of patients with Mucosa Associated Lymphoma Tissue (MALT) lymphoma across multiple harmonized cohorts. , 2021, 2021, 1666-1669.		0
201	Kinetics of Mononuclear Cell Subpopulations in the Peripheral Blood of Patients with Giant Cell Arteritis During the Acute Phase of the Disease: The Role of Steroids. Mediterranean Journal of Rheumatology, 2022, 33, 102.	0.3	0
202	A past medical history of autoimmune disease predicts a future with fewer relapses in patients with ANCA-associated vasculitis. Clinical and Experimental Rheumatology, 2022, 40, 741-750.	0.4	0